Science & Research
New Genetic Discovery Enhances Cancer Immunotherapy Potential
A groundbreaking genetic discovery could significantly improve the effectiveness of cancer immunotherapy, offering new hope for patients with certain types of cancer.
Lantern Pharma's Starlight Therapeutics Receives FDA Clearance for GBM Combination Trial
Starlight Therapeutics, a subsidiary of Lantern Pharma, has been cleared by the FDA to begin a Phase Ib/2a clinical trial for a novel combination therapy targeting glioblastoma multiforme, a move that could significantly impact treatment options for this aggressive brain cancer.
Soligenix Inc. Advances Rare Disease Treatment with HyBryte Platform, Highlighting Growing Need in Aging Population
Soligenix Inc. is making strides in treating cutaneous T-cell lymphoma, a rare skin cancer affecting older adults, underscoring the urgent need for innovative treatments in the face of an aging population and the prevalence of rare diseases.
Excessive Screen Time Linked to Higher Cardiometabolic Risks in Youth, Study Finds
New research highlights the association between excessive screen time and increased cardiometabolic disease risks in children and young adults, emphasizing the need for balanced daily routines to protect long-term health.
EnPlusOne Biosciences Aims to Revolutionize RNA Therapeutics with Enzymatic Synthesis
EnPlusOne Biosciences, under the leadership of CEO Clare Murray Ph.D., is pioneering an enzymatic approach to RNA synthesis, addressing the limitations of current methods and paving the way for scalable, pure, and environmentally friendly RNA therapeutics.
Quantum BioPharma Ltd. Reports Positive Phase 1 Safety Results for Lucid-MS
Quantum BioPharma Ltd. announces positive Phase 1 safety results for Lucid-MS, a potential treatment for multiple sclerosis, marking a significant step towards efficacy trials and FDA application.
Soligenix Inc. Advances in Rare Disease Therapeutics with HyBryte(TM) Platform
Soligenix Inc. (NASDAQ: SNGX) is making significant strides in the development of treatments for rare diseases, particularly with its HyBryte(TM) platform for cutaneous T-cell lymphoma, addressing a critical need for FDA-approved therapies in an underserved market.
Epic Medical Research Joins hyperCORE International's Global Network, Expanding Clinical Trial Capabilities
Epic Medical Research's inclusion in hyperCORE International's global partner site network signifies a strategic expansion in clinical research capabilities, enhancing the delivery of innovative and efficient clinical trial solutions across a wide range of therapeutic areas.
Study Links Inflammation Markers in Diabetics to Depression Treatment Efficacy
A recent study reveals that inflammation markers in diabetics significantly affect the outcomes of depression treatments, highlighting the need for targeted therapeutic approaches.
Clene Inc. to Showcase Neurodegenerative Disease Treatments at Canaccord 45th Annual Growth Conference
Clene Inc. will present its innovative treatments for neurodegenerative diseases at the Canaccord 45th Annual Growth Conference, highlighting potential advancements in ALS and MS therapy.
Wearable Devices Ltd. Enhances Patent Portfolio with New Gesture and Voice-Control Interface Technology
Wearable Devices Ltd. secures a continuation patent for its gesture and voice-control interface, marking a significant advancement in touchless technology and human-computer interaction.
Intensity Therapeutics Secures $6.6 Million to Advance Cancer Treatment Research
Intensity Therapeutics raises $6.6 million through an At-the-Market offering to fund clinical trials for its innovative cancer therapy, INT230-6, marking a significant step forward in the fight against cancer.
Soligenix Inc. Advances in Treating Rare Skin Cancer with HyBryte Platform
Soligenix Inc.'s progress with its HyBryte platform for treating cutaneous T-cell lymphoma highlights the critical need for innovative therapies in addressing rare diseases among the aging population.
Neutra Life Sciences Expands Clinical Research Capabilities Through Strategic Joint Ventures
Neutra Life Sciences, a subsidiary of Neutra Corp, is expanding its clinical research footprint through new joint venture partnerships in podiatry, radiation oncology, and dermatology, signaling a strategic shift towards life sciences and away from hemp-based cannabis ventures.
Exploring the Link Between TMJ/TMD and Severe Headaches Through Neuromuscular Dentistry
A new article highlights the connection between TMJ/TMD disorders and severe headaches, offering insights into treatment options like Sphenopalatine Ganglion Blocks and Neuromuscular Dentistry.
ESGold Corp. Discovers Significant Similarities Between Montauban Site and Renowned Broken Hill Deposit
ESGold Corp.'s Montauban mine site in Quebec shows promising similarities to Australia's Broken Hill deposit, indicating potential for a significant polymetallic discovery and sustainable mining operations.
Genetic Breakthrough Could Personalize Brain Tumor Treatment
Researchers at the University of Kentucky have discovered a genetic biomarker that could help predict which glioblastoma patients may benefit from the drug bevacizumab, offering a new avenue for personalized cancer treatment.
Community Foundation of The Virgin Islands Launches Grant Program for Environmental Studies in the Caribbean
The Community Foundation of the Virgin Islands is offering grants to support environmental initiatives in the Caribbean, addressing critical challenges like biodiversity loss and climate change.
BIO 2025 Trend Report Highlights Biotech's Shift Towards Scalability and Human-Centric Innovation
The BIO 2025 Pulse of the Industry Report by Norvell Jefferson underscores the biotech sector's evolution towards scalable, meaningful innovations that prioritize human-centric approaches and strategic branding.
Oragenics Inc. Advances ONP-002 Phase IIa Trial with Southern Star Research for Concussion Treatment
Oragenics Inc. partners with Southern Star Research to conduct a Phase IIa trial for ONP-002, an intranasal therapy aimed at treating mild traumatic brain injuries, highlighting a significant step towards addressing the unmet needs in concussion care.
Aston Bay Holdings Ltd. Initiates Summer Field Program at Epworth Project
Aston Bay Holdings Ltd. has commenced its summer field program at the Epworth copper-silver-zinc-cobalt project in Nunavut, targeting high-priority areas for sediment-hosted copper mineralization.
D-Wave Quantum Inc. Launches Advanced Cryogenic Packaging Initiative to Scale Quantum Processor Development
D-Wave Quantum Inc. announces a strategic initiative to advance cryogenic packaging technology, aiming to scale quantum processor development and extend its leadership in quantum computing systems.
Soligenix Inc. Achieves Significant Milestone in Phase 2a Study for Behçet’s Disease Treatment
Soligenix Inc. reports promising results from its Phase 2a study of SGX945 for Behçet’s Disease, showing potential to address unmet medical needs in inflammatory conditions.
Lantern Pharma Achieves Milestone in Phase 2 HARMONIC Trial for Non-Smoker NSCLC Patients in Japan
Lantern Pharma completes targeted enrollment for its Phase 2 HARMONIC trial in Japan, marking a significant step in its international expansion and offering hope for never-smoker NSCLC patients.
Amerigo Scientific Enhances Research Accuracy with Premium Carotenoid Standards
Amerigo Scientific's introduction of high-purity carotenoid standards marks a significant advancement in ensuring reliable and reproducible analytical results for industries reliant on precise carotenoid quantification.
Quantum Art Achieves Milestone with 200-Ion Chain for Scalable Quantum Computing
Quantum Art's demonstration of a stable 200-ion chain marks a significant step toward scalable, commercially viable quantum computing by validating key architectural innovations.
NanoViricides' NV-387 Emerges as Potential Breakthrough in Combatting Measles Outbreaks
NanoViricides Inc. announces its drug candidate NV-387 could significantly impact the treatment of measles, addressing a critical gap in antiviral medications amid rising global outbreaks.
Royalty Management's Expanded Sampling Reveals Valuable Rare Earth Elements in Jamaica
Royalty Management Holding Corporation's expanded sampling at T.R. Mining in Jamaica uncovers significant rare earth elements alongside titanium and vanadium, promising economic benefits and low-cost feedstock sources.
BTT Brain Wellness Institute Pioneers Non-Invasive Brain Health Solutions
The BTT Brain Wellness Institute, founded by Dr. M. Marc Abreu, introduces innovative, non-invasive treatments to optimize brain function, marking a significant advancement in personalized brain health care.
Calidi Biotherapeutics Inc. Receives FDA Fast Track Designation for CLD-201 in Soft Tissue Sarcoma
Calidi Biotherapeutics Inc. has been granted FDA Fast Track designation for its CLD-201 treatment, marking a significant step forward in the development of therapies for soft tissue sarcoma and other cancers.